Search clinical trials for: rAvPAL-PEG 0.003 mg/kg

Total 1039 results

BioMarin Pharmaceutical

Completed

Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU

Phenylketonuria

United States
Lee's Pharmaceutical Limited

Suspended

Antiplatelet Thrombolysin (Anfibatide) Phase 1 Clinical Trial in Healthy Volunteers

Antiplatelet Drug

China
BioMarin Pharmaceutical

Completed

Safety and Tolerability Study of rAvPAL-PEG to Treat Phenylketonuria

Phenylketonuria

United States
BioMarin Pharmaceutical

Completed

Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)

Phenylketonuria

United States
BioMarin Pharmaceutical

Completed

Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU

Phenylketonuria (PKU)

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery

Acute Pain

United States
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma

Melanoma

United States
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC

Terminated

An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis

Colitis, Ulcerative

United States, Poland, Germany, France, India, Romania, Serbia, Ukraine, Israel, Canada, Netherlands, Sweden, New Zealand, Russian Federation, Australia, Belgium, Hungary, Bulgaria, Slovakia, Latvia, Lithuania, Austria
Joben Bio-Medical Co., Ltd.
Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General... and other collaborators

Unknown

Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients

Radiodermatitis

Taiwan
University of California, San Francisco
Bill and Melinda Gates Foundation; Wellcome Trust; Malaria Research and Training... and other collaborators

Completed

Phase2a Primaquine Dose Escalation Study

Malaria

Mali
Keymed Biosciences Co.Ltd

Not yet recruiting

A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
GlaxoSmithKline

Completed

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects (DEMAND I)

Muscular Dystrophies

France, United States
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Healthy Subjects

United States
Healthgen Biotechnology Corp.

Recruiting

Study of OsrhAAT or Placebo in Healthy Volunteers

Emphysema Secondary to Congenital AATD

United States
Gangnam Severance Hospital

Completed

Remimazolam Bolus for General Anesthesia

Loss of Consciousness

Korea, Republic of
Aileron Therapeutics, Inc.

Completed

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

Growth Hormone Deficiency

United States
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

Influenza

United States
Crucell Holland BV
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

Influenza

United States
Providence Health & Services

Completed

α-TEA in Advanced Cancer

Metastatic Sarcoma | Metastatic Carcinoma | Metastatic Lymphoma

United States
Healthgen Biotechnology Corp.

Completed

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

Ascites Hepatic

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Healthy Elderly Subjects

China
MedImmune LLC

Completed

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Relapsed/Refractory Aggressive B-cell Lymphomas

United States
Eisai Co., Ltd.

Completed

A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease

Japan
Integro Theranostics

Recruiting

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

Breast Cancer | DCIS | Invasive Duct Carcinoma of Breast

United States
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
The First Affiliated Hospital with Nanjing Medical University; Cancer Institute... and other collaborators

Unknown

Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia (PEG-rhG-CSF)

Neutropenia

China
Suzhou Transcenta Therapeutics Co., Ltd.

Completed

A Phase I Study of MSB2311 in Advanced Solid Tumors

Advanced Solid Tumors

United States
Eisai Inc.
Biogen

Active, not recruiting

A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease

Alzheimer's Disease

United States, Canada, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, United Kingdom
ReveraGen BioPharma, Inc.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Completed

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States, Canada, United Kingdom, Sweden, Australia, Israel
BioMarin Pharmaceutical

Terminated

Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Belgium, Netherlands, France, United Kingdom, Italy
Bill & Melinda Gates Medical Research Institute

Recruiting

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

Malaria

United States
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Gastric/Gastroesophageal Junction Cancer

China
BioMarin Pharmaceutical

Terminated

Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

Belgium, Netherlands, Italy, Sweden
Bayer

Completed

A Study to Learn More About the Safety and the Blood Level of BAY1747846 Given as Injection Into the Vein at Increasing Single Doses in Chinese Healthy Male Participants

Healthy Volunteers | Contrast Enhancement in Magnetic Resonance Imaging

China
Seoul National University Hospital

Withdrawn

Optimal Dose of i.v Oxycodone for Postoperative Pain After Laparoscopic Colorectal Surgery

Pain

Korea, Republic of
Pfizer

Withdrawn

Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

Dyslipidemia | Hypercholesterolemia
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Duke University
National Heart, Lung, and Blood Institute (NHLBI); American Heart Association

Completed

Ketone Pharmacokinetic Study in HFrEF

Heart Failure With Reduced Ejection Fraction

United States
Seoul National University Hospital

Completed

Optimal Dose of i.v Oxycodone for Postoperative Pain

Pain

Korea, Republic of
Acceleron Pharma, Inc., a wholly-owned subsidiary...

Recruiting

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) (CADENCE)

Hypertension, Pulmonary

United States, Belgium, France, Germany, Israel, Italy, Spain, Sweden, United Kingdom, Poland, Canada
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Lpath, Inc.

Completed

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers

Healthy Subjects

United States
CARE Pharma Shanghai Ltd.

Recruiting

A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH

Hemolysis | PNH

China
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

Asthma

United States
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

Healthy

United States
Pfizer

Completed

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
Sameem M. Abedin, MD

Recruiting

Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)

Graft-versus-host Disease

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma

Asthma

United States, Canada
aTyr Pharma, Inc.
Foundation for Sarcoidosis Research

Completed

Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

Pulmonary Sarcoidosis

United States
GPCR Therapeutics, Inc.

Completed

Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

Multiple Myeloma | Hodgkin Disease | Non-Hodgkin Lymphoma

Taiwan
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States, Canada, France, Singapore, Taiwan

Search clinical trials for: rAvPAL-PEG 0.003 mg/kg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations